vs
ANI PHARMACEUTICALS INC（ANIP）とTraeger, Inc.（COOK）の財務データ比較。上の社名をクリックして会社を切り替えられます
ANI PHARMACEUTICALS INCの直近四半期売上が大きい（$247.1M vs $145.4M、Traeger, Inc.の約1.7倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs -11.8%、差は23.0%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs -13.8%）。ANI PHARMACEUTICALS INCの直近四半期フリーキャッシュフローが多い（$29.1M vs $14.2M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 0.2%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
Traeger, Inc.は高品質な木質ペレットグリル、関連アクセサリー、専用木質ペレット燃料を設計・製造・販売する企業です。主に北米、欧州、オーストラリアを市場とし、小売パートナーと直販ルートを通じて一般家庭や飲食店顧客に製品を提供しています。
ANIP vs COOK — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $145.4M |
| 純利益 | $27.5M | $-17.2M |
| 粗利率 | — | 37.4% |
| 営業利益率 | 14.1% | -8.0% |
| 純利益率 | 11.1% | -11.8% |
| 売上前年比 | 29.6% | -13.8% |
| 純利益前年比 | 367.5% | -147.2% |
| EPS（希薄化後） | $1.14 | $-0.13 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $145.4M | ||
| Q3 25 | $227.8M | $125.4M | ||
| Q2 25 | $211.4M | $145.5M | ||
| Q1 25 | $197.1M | $143.3M | ||
| Q4 24 | $190.6M | $168.6M | ||
| Q3 24 | $148.3M | $122.0M | ||
| Q2 24 | $138.0M | $168.5M | ||
| Q1 24 | $137.4M | $144.9M |
| Q4 25 | $27.5M | $-17.2M | ||
| Q3 25 | $26.6M | $-89.8M | ||
| Q2 25 | $8.5M | $-7.4M | ||
| Q1 25 | $15.7M | $-778.0K | ||
| Q4 24 | $-10.3M | $-7.0M | ||
| Q3 24 | $-24.2M | $-19.8M | ||
| Q2 24 | $-2.3M | $-2.6M | ||
| Q1 24 | $18.2M | $-4.7M |
| Q4 25 | — | 37.4% | ||
| Q3 25 | — | 38.7% | ||
| Q2 25 | — | 39.2% | ||
| Q1 25 | — | 41.5% | ||
| Q4 24 | — | 40.9% | ||
| Q3 24 | — | 42.3% | ||
| Q2 24 | — | 42.9% | ||
| Q1 24 | — | 43.2% |
| Q4 25 | 14.1% | -8.0% | ||
| Q3 25 | 15.9% | -66.5% | ||
| Q2 25 | 6.6% | -4.2% | ||
| Q1 25 | 13.3% | 2.4% | ||
| Q4 24 | -2.3% | -0.1% | ||
| Q3 24 | -13.8% | -6.1% | ||
| Q2 24 | 3.7% | 2.8% | ||
| Q1 24 | 14.8% | -0.1% |
| Q4 25 | 11.1% | -11.8% | ||
| Q3 25 | 11.7% | -71.6% | ||
| Q2 25 | 4.0% | -5.1% | ||
| Q1 25 | 8.0% | -0.5% | ||
| Q4 24 | -5.4% | -4.1% | ||
| Q3 24 | -16.3% | -16.2% | ||
| Q2 24 | -1.7% | -1.5% | ||
| Q1 24 | 13.2% | -3.2% |
| Q4 25 | $1.14 | $-0.13 | ||
| Q3 25 | $1.13 | $-0.67 | ||
| Q2 25 | $0.36 | $-0.06 | ||
| Q1 25 | $0.69 | $-0.01 | ||
| Q4 24 | $-0.45 | $-0.06 | ||
| Q3 24 | $-1.27 | $-0.15 | ||
| Q2 24 | $-0.14 | $-0.02 | ||
| Q1 24 | $0.82 | $-0.04 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $19.6M |
| 総負債低いほど良い | — | $403.3M |
| 株主資本純資産 | $540.7M | $170.8M |
| 総資産 | $1.4B | $676.0M |
| 負債/資本比率低いほどレバレッジが低い | — | 2.36× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $19.6M | ||
| Q3 25 | $262.6M | $5.9M | ||
| Q2 25 | $217.8M | $10.3M | ||
| Q1 25 | $149.8M | $12.0M | ||
| Q4 24 | $144.9M | $15.0M | ||
| Q3 24 | $145.0M | $16.9M | ||
| Q2 24 | $240.1M | $18.0M | ||
| Q1 24 | $228.6M | $23.6M |
| Q4 25 | — | $403.3M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $403.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $540.7M | $170.8M | ||
| Q3 25 | $505.8M | $186.1M | ||
| Q2 25 | $436.8M | $274.2M | ||
| Q1 25 | $418.6M | $279.6M | ||
| Q4 24 | $403.7M | $276.4M | ||
| Q3 24 | $405.9M | $279.8M | ||
| Q2 24 | $455.8M | $297.3M | ||
| Q1 24 | $452.0M | $294.6M |
| Q4 25 | $1.4B | $676.0M | ||
| Q3 25 | $1.4B | $689.6M | ||
| Q2 25 | $1.3B | $780.6M | ||
| Q1 25 | $1.3B | $825.6M | ||
| Q4 24 | $1.3B | $830.7M | ||
| Q3 24 | $1.3B | $818.1M | ||
| Q2 24 | $920.8M | $842.4M | ||
| Q1 24 | $914.5M | $862.1M |
| Q4 25 | — | 2.36× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.46× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $15.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $14.2M |
| FCFマージンFCF / 売上 | 11.8% | 9.8% |
| 設備投資強度設備投資 / 売上 | 0.5% | 0.9% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | — |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $13.6M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $15.5M | ||
| Q3 25 | $44.1M | $7.6M | ||
| Q2 25 | $75.8M | $18.3M | ||
| Q1 25 | $35.0M | $-20.8M | ||
| Q4 24 | $15.9M | $7.5M | ||
| Q3 24 | $12.5M | $15.1M | ||
| Q2 24 | $17.4M | $13.9M | ||
| Q1 24 | $18.3M | $-12.6M |
| Q4 25 | $29.1M | $14.2M | ||
| Q3 25 | $38.0M | $6.4M | ||
| Q2 25 | $71.8M | $15.7M | ||
| Q1 25 | $32.5M | $-22.7M | ||
| Q4 24 | $13.5M | $5.5M | ||
| Q3 24 | $7.7M | $12.8M | ||
| Q2 24 | $13.0M | $11.8M | ||
| Q1 24 | $13.7M | $-18.3M |
| Q4 25 | 11.8% | 9.8% | ||
| Q3 25 | 16.7% | 5.1% | ||
| Q2 25 | 34.0% | 10.8% | ||
| Q1 25 | 16.5% | -15.8% | ||
| Q4 24 | 7.1% | 3.3% | ||
| Q3 24 | 5.2% | 10.5% | ||
| Q2 24 | 9.4% | 7.0% | ||
| Q1 24 | 10.0% | -12.6% |
| Q4 25 | 0.5% | 0.9% | ||
| Q3 25 | 2.7% | 0.9% | ||
| Q2 25 | 1.9% | 1.8% | ||
| Q1 25 | 1.3% | 1.3% | ||
| Q4 24 | 1.3% | 1.2% | ||
| Q3 24 | 3.2% | 1.9% | ||
| Q2 24 | 3.2% | 1.2% | ||
| Q1 24 | 3.3% | 3.9% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
COOK
| Grills | $60.6M | 42% |
| Accessories | $49.2M | 34% |
| Consumables | $35.5M | 24% |
